We are live on ! Find out more
BPMC

Blueprint Medicines
BPMC

Delisted

BPMC was delisted on the 17th of July, 2025.

Back to rankings

175 hedge funds and large institutions have $4B invested in Blueprint Medicines in 2018 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 55 increasing their positions, 63 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 24

24% more capital invested

Capital invested by funds: $3.23B → $4B (+$771M)

20% more funds holding in top 10

Funds holding in top 10: 10 → 12 (+2)

3% more funds holding

Funds holding: 170 → 175 (+5)

1% more call options, than puts

Call options by funds: $16.4M | Put options by funds: $16.3M

0.15% more ownership

Funds ownership: 99.69% → 99.84% (+0.15%)

13% less repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 63

Holders
175
Holders Change
+5
Holders Change %
+2.94%
% of All Funds
4.01%
Holding in Top 10
12
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+20%
% of All Funds
0.28%
New
31
Increased
55
Reduced
63
Closed
24
Calls
$16.4M
Puts
$16.3M
Net Calls
+$156K
Net Calls Change
-$13.1M

Top Buyers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
+$30.2M
2
VOYA Investment Management
VOYA Investment Management
Georgia
+$25.7M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$17.9M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$15.9M
5
BlackRock
BlackRock
New York
+$15.2M

Top Sellers

Rank Fund Capital Flow
1
TCM
TimesSquare Capital Management
New York
-$23.2M
2
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$16.4M
3
Morgan Stanley
Morgan Stanley
New York
-$13.5M
4
OM
Opaleye Management
Massachusetts
-$11.6M
5
BI
BVF Inc
California
-$9.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
MCM
176
Moore Capital Management
New York
– -$2.64M -35,000 Closed
ACPU
177
Arrowgrass Capital Partners (US)
Delaware
– -$1.98M -26,234 Closed
Susquehanna International Group
178
Susquehanna International Group
Pennsylvania
– -$1.55M -17,966 Closed
Janus Henderson Group
179
Janus Henderson Group
United Kingdom
– -$1.13M -15,000 Closed
WIM
180
Waverton Investment Management
United Kingdom
– -$1.11M -14,760 Closed
SSA
181
Schonfeld Strategic Advisors
New York
– -$1.02M -13,588 Closed
ARTA
182
A.R.T. Advisors
New York
– -$842K -11,177 Closed
FRM
183
Fox Run Management
Connecticut
– -$835K -11,067 Closed
Tudor Investment Corp
184
Tudor Investment Corp
Connecticut
– -$798K -10,582 Closed
SEC
185
Seven Eight Capital
New York
– -$762K -10,100 Closed
Squarepoint
186
Squarepoint
New York
– -$600K -7,950 Closed
OAM
187
Oberweis Asset Management
Illinois
– -$505K -6,700 Closed
Parallax Volatility Advisers
188
Parallax Volatility Advisers
California
– -$488K -6,468 Closed
OAM
189
Oxford Asset Management
United Kingdom
– -$449K -5,812 Closed
MS
190
Maven Securities
Jersey
– -$388K -5,000 Closed
Arrowstreet Capital
191
Arrowstreet Capital
Massachusetts
– -$234K -3,100 Closed
AGM
192
Alpine Global Management
New York
– -$226K -3,000 Closed
TRCT
193
Tower Research Capital (TRC)
New York
– -$190K -2,513 Closed
Simplex Trading
194
Simplex Trading
Illinois
– -$111K -1,284 Closed
Pacer Advisors
195
Pacer Advisors
Pennsylvania
– -$75K -1,000 Closed
FMA
196
FNY Managed Accounts
New York
– -$3K -50 Closed
STA
197
Summit Trail Advisors
New York
– -$1K -10 Closed
WAP
198
Wealthcare Advisory Partners
Pennsylvania
– +$86 +1 New
4 5 6 7
8

BPMC Hedge Fund Activity: Q1 2018 in Review

175 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q1 2018, worth a combined $4B — up 24% from $3.23B a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new BPMC positions and 24 closed out — a net gain of 7 holders — while 55 added to existing stakes and 63 trimmed.

The largest buyer was Artal Group, adding an estimated $30.2M. The largest seller was TimesSquare Capital Management, cutting an estimated $23.2M.

  • 175 institutional investors held Blueprint Medicines (BPMC) as of Q1 2018, up from 170 in Q4 2017.
  • Funds reported $4B of Blueprint Medicines stock for Q1 2018, up 24% quarter-over-quarter.
  • 31 funds opened new Blueprint Medicines positions in Q1 2018 and 24 closed out, a net change of +7 holders.
  • The largest Blueprint Medicines buyer in Q1 2018 was Artal Group, an estimated $30.2M added.
  • The largest Blueprint Medicines seller in Q1 2018 was TimesSquare Capital Management, an estimated $23.2M sold.

Based on aggregated 13F filings for Q1 2018.